Cochrane · systematic review · CD011353
Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
Tam, KW, Wu, MY, Siddiqui, FJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
9
No studies
2
Included studies
NR
No studies 2 · 18.2%Ungraded 0 · 0%Very low 5 · 45.5%Low 2 · 18.2%Moderate 2 · 18.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Omega‐3 fatty acids versus placebo for dialysis vascular access outcomes in AVF patients with ESKD
Population: Dialysis vascular access outcomes in AVF patients with ESKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Loss of patency: Omega‐3 fatty acids vs placebo | RR 1.01 [0.84, 1.21] | 1 study · 536 participants | Moderate |
Serious adverse events: death Omega‐3 fatty acids vs placebo | RD 0 | 1 study · 567 participants | Moderate Downgraded: risk of bias |
Serious adverse events: hospitalisation Omega‐3 fatty acids vs placebo | RD 0 | 1 study · 567 participants | Low |
Serious adverse events: cardiovascular events Omega‐3 fatty acids vs placebo | no estimate extracted | NR | No studies |
Serious adverse events: major bleeding Omega‐3 fatty acids vs placebo | no estimate extracted | NR | No studies |
Omega‐3 fatty acids compared to Placebo for dialysis vascular access outcomes in AVG patients with ESKD
Population: dialysis vascular access outcomes in AVG patients with ESKD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Loss of patency by 6 months Omega‐3 fatty acids vs Placebo | RR 0.91 [0.36, 2.28] | 2 studies · 41 participants | Very low Downgraded: risk of bias |
Loss of patency by 12 months Omega‐3 fatty acids vs Placebo | RR 0.59 [0.27, 1.31] | 2 studies · 220 participants | Very low Downgraded: risk of bias |
Serious adverse events: death Omega‐3 fatty acids vs Placebo | RD 0.01 | 4 studies · 261 participants | Low Downgraded: risk of bias |
Serious adverse events: hospitalisation Omega‐3 fatty acids vs Placebo | RD 0.08 | 3 studies · 65 participants | Very low Downgraded: risk of bias |
Serious adverse events: cardiovascular events Omega‐3 fatty acids vs Placebo | no estimate extracted | 4 studies · 261 participants | Very low Downgraded: risk of bias |
Serious adverse events: major bleeding Omega‐3 fatty acids vs Placebo | RD 0.08 | 3 studies · 65 participants | Very low Downgraded: risk of bias |